HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Initial experiences with "Oranienburg" slow-release theophylline in asthma therapy of children and adolescents].

Abstract
Experiences in 50 patients show that Theophyllin retard Oranienburg (280 mg theophylline) could be used as an effective bronchospasmolytic drug on conditions of mono- and combination-therapy. Advantages of this preparation are improvement of the compliance and an undisturbed night-sleep in patients. However an optimum dosage is hardly maintained in children by the present dose of a single tablet of 280 theophylline content. The effectiveness in therapy of childhood asthma could be improved by stronger sustained release effect and different doses of tablets.
AuthorsV Sollich, R Schuster, W Thal, E Köhler, H Walther
JournalKinderarztliche Praxis (Kinderarztl Prax) Vol. 58 Issue 1 Pg. 45-8 (Jan 1990) ISSN: 0023-1495 [Print] Germany
Vernacular TitleErste Erfahrungen mit Theophyllin retard "Oranienburg" in der Asthmatherapie bei Kindern und Jugendlichen.
PMID2332947 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Theophylline
Topics
  • Adolescent
  • Asthma (drug therapy)
  • Child
  • Delayed-Action Preparations
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Metabolic Clearance Rate (physiology)
  • Theophylline (administration & dosage, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: